Fennec Pharmaceuticals
Quarterly Financials
| Values in thousands | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
|---|---|---|---|---|
Revenue | $6,974 | $7,262 | $25,377 | $9,735 |
Gross Profit | 5,617 | 6,654 | 24,827 | 9,050 |
EBITDA | -4,685 | -4,483 | 14,594 | -1,697 |
EBIT | -4,710 | -4,509 | 13,871 | -1,767 |
Net Income | -5,735 | -5,553 | 12,837 | -2,682 |
Net Change In Cash | 6,974 | 7,262 | 25,377 | 9,735 |
Free Cash Flow | -2,206 | -8,040 | 38,872 | -4,974 |
Cash | 40,320 | 43,047 | 51,131 | 13,201 |
Basic Shares | 27,371 | 27,297 | 31,091 | 26,833 |
Annual Financials
| Values in thousands | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|
Revenue | $21,252 | $1,535 | $170 | $170 |
Gross Profit | 19,993 | 1,449 | 0 | 170 |
EBITDA | -12,364 | -22,587 | -123 | -17,885 |
EBIT | -12,651 | -22,736 | -17,346 | -18,287 |
Net Income | -16,045 | -24,839 | -17,456 | -17,922 |
Net Change In Cash | 21,252 | 1,535 | 170 | 170 |
Cost of Revenue | -9,244 | 16,694 | ||
Free Cash Flow | -17,143 | -18,058 | -14,222 | -15,595 |
Cash | 13,269 | 23,774 | 21,100 | 30,344 |
Basic Shares | 26,574 | 26,275 | 26,006 | 23,704 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-09-30 | -$0.21 |
2024-06-30 | -$0.20 |
2024-03-31 | $0.47 |
2023-12-31 | -$0.10 |
